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Background. Proinﬂammatory cytokines are prime candidates as causative agents of the metabolic changes that eventually result
in tuberculosis-associated weight loss. Microbial products and cytokines such as TNF and IL-1 increase leptin expression dose
dependently in adipose tissue. Leptin plays an important role in cellular immunity. Objectives. In this study, we investigated serum
leptin and TNF-α levels before and after antituberculosis therapy in patients with active pulmonary tuberculosis (TB). Methods.
Twenty ﬁve in patients with active pulmonary TB and 18 healthy controls participated in the study. Leptin and TNF-α levels were
measured before treatment and six months after the treatment and they were compared with the control group. Body mass index
(BMI) and chest X-rays before and after the treatment were also evaluated. Results. The leptin levels before and after the treatment
were1.66±1.68ng/mLand3.26±3.81ng/mL,respectively.Theleptinlevelsoftuberculouspatientsweresigniﬁcantthaninhealthy
patients (P<. 05). The BMI was 19.36 ± 2.55kg/m
2 before the treatment and 22.87 ± 3.13kg/m
2 after the treatment. The TNF-α
level was 23.19±12.78pg/mL before the treatment and 15.95±6.58pg/mL after the treatment. There was no correlation between
leptin and TNF-α levels. Leptin levels were low in patients who had sequela lesion on chest radiographs. Conclusion.L e p t i nl e v e l s
are suppressed in tuberculous patients and low leptin levels may contribute to increased susceptibility to infection and recovery
with sequela lesions.
Copyright © 2007 Hakan Buyukoglan et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Tuberculosis (TB) is a major cause of death around the
world, with most of the 1.5 million deaths per year at-
tributable to the disease occurring in developing countries
[1]. One of the most important and common complaints
of tuberculous patients which also aﬀects the immune sta-
tus is weight loss. Antimycobacterial treatment often in-
creases weight but patients may remain underweight even six
months after the successful chemotherapy. Although wast-
ing is probably one of the determinants of the disease sever-
ity and outcome, the pathogenesis of tuberculosis-associated
wasting is largely unknown [2].
Some cytokines promote inﬂammation and are called
proinﬂammatory cytokines (tumor necrosis factor-alfa
(TNF-α), interleukin (IL)-1, IL-6, and IL-8), whereas other
cytokines suppresstheactivityofproinﬂammatorycytokines
and are called anti-inﬂammatory cytokines (IL-4, IL-10, and
IL-13) [3]. Proinﬂammatory cytokines are prime candidates
as causative agents of the metabolic changes that eventually
resultintuberculosis-associatedweightloss.TNF-αhassome
harmful eﬀects, such as acute-phase pathophysiologic events
including fever and tissue necrosis. It also plays a protective
role against mycobacterial infection [3, 4].
Leptin, the product of the “ob” gene, regulates food in-
take and energy expenditure. In humans, circulating lep-
tin levels are increased in obesity and are regulated by fast-
ing, feeding, and body weight changes [5–7]. In addition
to playing a role in energy regulation, leptin also regulates
endocrine and immune functions [6–10]. Leptin links the
proinﬂammatory T-helper 1 immune response to the nutri-
tional status and the energy balance. It has been suggested
that leptin mediates anorexia in chronic inﬂamatory states
[11].
Therelationshipbetweenleptinandpulmonarytubercu-
losis is not completely understood. There are very few stud-
ies relating the level of leptin and TNF-α before and after
antituberculosis therapy and their results are contradictory.2 Mediators of Inﬂammation
Forthis reason, wehave decidedtoinvestigate the roleof lep-
tin and TNF-α in tuberculosis.
2. MATERIALS AND METHODS
Twenty ﬁve inpatients (19 males (mean ± SD age, 35.47 ±
13.91 years) and 6 females (mean ± SD age, 37.66 ± 18.20
years)) with active pulmonary TB (mean ± SD age, 36.0 ±
14.66 years) and 18 healthy controls 10 males (mean ± SD
age, 38.60 ± 15.57 years and eight females (mean ± SD age
28.75 ± 5.59 years)) participated in the study. All patients
were recruited from the Erciyes University Medical School,
Outpatient Clinic of Pulmonology. On entry, all patients had
positive smear for acid-fast bacilli in sputum or bronchial
lavage and subsequent cultures of these specimens yielded
tuberclebacilli.Noneofthepatientshadanyevidenceofcon-
comitant bacterial or viral infections as indicated by sputum
and blood cultures and viral serologic study including HIV.
All patients were administered anti-TB therapy in which iso-
niazid (H), rifampicin (R), pyrazinamide (Z), and strepto-
mycin (S) or ethambutol (E) were used. All the patients with
TB were treated with standard therapy for active TB regimen
which consists of 2 months of initial phase of HRZ E/S fol-
lowed by a 4-month continuation phase of HR. Dosage rec-
ommendations of treatment of TB were H 5mg/kg, maxi-
mum 300mg, R 10mg/kg maximum 600mg, Z 15–30mg/kg
maximum 2g, E 15–25mg/kg maximum 1500mg after 1
month reduced to 1000mg, S 15mg/kg maximum 1g.
All patients had pulmonary symptoms such as cough,
fever,andhemoptysiscompatiblewithTB.Toassessthepres-
ence, form, spread, and size of the TB cavities and inﬁltra-
tions in the lungs, all 25 patients received plain posteroan-
terior and lateral chest X-rays. To avoid observer bias, three
pulmonary physicians initially assessed the X-rays indepen-
dently. The patients were divided radiologically into three
categories; minimal, moderate-advanced, and far-advanced.
In minimal TB, the lesions include those of slight to mod-
erate density but they do not contain demonstrable cavita-
tions. They may involve a small part of one or both lungs,
but the total extent, regardless of distribution, should not ex-
ceed the volume of the lung on one side that occupies the
space above the second condrosternal junction and the spine
of the fourth thoracic vertebra or the body of the ﬁfth tho-
racic vertebra. Moderate-advanced TB lesions include dis-
seminated lesions of slight to moderate density that may ex-
tend throughout the total volume of one lung or the equiv-
alent in both lungs; dense or conﬂuent lesions are limited in
extent to one third of the volume of one lung; and total di-
ameter of cavitations, if present, must be less than 4cm. In
far-advanced TB, total cavity diameters are more than 4cm
and lesions are more extensive than moderately advanced
[12].
Additionally, patients were assessed for loss of appetite,
weight loss, and any other weaknesses. Body mass index, ery-
throcyte sedimentation rate (ESR), and body temperature
were measured initially and after therapy. Body mass index
(BMI) was measured as body weight (kg)/square of height
(m2).Acontrolgroupof18healthyvolunteersubjects(mean
Table 1: Demographic characteristics of patients with tuberculosis.
Number 25
Sex 19 men, 6 women
Age, (mean ± SD) years 36 ±14.66
Chest X-ray
Minimal (%) 8(%32)
Moderate-advanced (%) 10(%40)
Far-advanced (%) 7(%28)
Symptoms and ﬁndings
Weight loss (%) 17(%68)
Appetite (%) 12(%48)
Body mass index mean ± SD (kg/m2)1 9 .36 ±2.55
Body temperature, mean ± SD◦C3 7 .16 ±0.89
age was 34.99 ± 12.7 years) was also studied. We also evalu-
ated normal volunteers with chest X-rays, routine laboratory
tests,andphysicalexaminations.Noneofthecontrolsubjects
had any evidence of infection and systemic disorders. All pa-
tients and volunteers gave informed consent and the Erciyes
University Medical School, Ethics Committee, approved the
protocol.
2.1. Immunoassays
All serum samples were collected from the patients and the
control group before and after the 6 months of anti-TB ther-
apy. Serum samples for the measurement of leptin and TNF-
α level were drawn between 800–1000 hours and were pre-
served at −70◦C. All samples were assigned code numbers
a n dw e r ep r o c e s s e db ya ni n v e s t i g a t o r .S e r u ml e p t i nw a sd e -
termined using a commercially available radioimmunoassay
kit (DsLAB Inc., Tex, USA) and TNF-α using enzyme-linked
immunosorbent assay kits (Camarillo Inc., Calif, USA). The
intra-assaylevelofleptinwas2.75±0.10ng/mL((coeﬃcients
of variation (CV) 3.7%)) and interassay level of leptin was
2.88 ± 0.19ng/mL (CV 6.6%). The sensitivity of TNF was
6pg/mL(interassayCV:< 7.8%andintra-assayCV:< 7.2%).
Allsampleswereassayedinduplicate.Theseparameterswere
measured in patients after 6 months of anti-TB treatment.
2.2. Statisticalanalysis
The Kolmogorov-Smirnov test was used for conﬁrmation of
the parameters. All ﬁgures are presented as mean ± SD. T
tests and ANOVA were used for comparisons between the
groups. Spearman’s rank correlation was used to examine
the relationship between the expression individual cytokines
and clinical parameters. All P<. 05 were considered sig-
niﬁcant. Stastics were calculated with SPSS software, version
10.0 (SPSS Inc., Chicago, Ill, USA; http://www.spss.com).
3. RESULTS
DemographicdataofthepatientsaresummarizedinTable 1.
Themeanagesofthepatientsandthecontrolsweresimi-
lar (36.0±14.66 versus 34.22±12.9, resp.). Before treatment,H a k a nB u y u k o g l a ne ta l . 3
Table 2: Age, ESR, BMI, leptin, and TNF-α in controls and patients before and after tuberculosis therapy. Data presented as mean ± SD.
Parameters Patients Controls
Before therapy After therapy
Age 36 ±14.66 — 34.22 ±12.9
BMI (kg/m2) 19.36 ±2.55∗ 22.87 ±3.13 24.23 ±3.56
ESR (mm/h) 62.04 ±26.96 12.64 ±8.8† (Male < 25, female < 30)
Leptin (ng/mL) 1.66 ±1.68¶ 3.26 ±3.81‡ 15.74 ±9.12
TNF-α (pg/mL) 23.19 ±12.78§ 15.95 ±6.58 14.22 ±7.17
Comparison of case and control groups before therapy: ∗P<. 05, ¶P = .001, §P = .01.
Comparison of case and control groups after therapy: ‡P = .001.
Comparison of ESR before and after therapy: †P = .01.
the BMI of the patients was signiﬁcantly lower than the BMI
ofthecontrols(19.36±2.55kg/m2 versus 24.23±3.56kg/m2,
resp.; P = .001). After anti-TB therapy, the BMI of the pa-
tients increased signiﬁcantly and was similar to BMI of the
control subjects.
The mean serum leptin levels of the patients before treat-
ment were 1.66 ± 1.68ng/mL, while the mean serum leptin
levels of the controls were 15.74 ± 9.12ng/mL, and the dif-
ference between the two groups was statistically signiﬁcant
(P = .001). Treatment resulted in an increase in serum lep-
tin levels (3.26 ± 3.81ng/mL) but postreatment leptin lev-
els of the patients were still signiﬁcantlly lower than lep-
tin levels of the controls (P = .001). Although female pa-
tients had higher pretreatment leptin levels (2.17 ± 0.64 ver-
sus1.50±1.88ng/mL)andhigherposttreatmentleptinlevels
(4.38±2.95 versus3.18±4.26ng/mL)thanthemalepatients,
they were not statistically signiﬁcant.
Serum TNF-α levels before treatment were higher in
the patients than in the controls (23.19 ± 12.78 versus
14.22 ± 7.17pg/mL, resp.; P<. 05). Postreatment TNF-
α levels were similar in both groups. There was no sig-
niﬁcant association between leptin and TNF-α concentra-
tions. No correlation was found between BMI, body temper-
ature, TNF-α, and leptin levels before treatment (r = 0.03,
r = 0.33, r =− 0.15). Leptin and TNF-levels are shown in
Table 2.
The concentrations of TNF-α and leptin in the pa-
tients according to chest X-ray ﬁndings are presented in
Table 3.
After treatment, there was a substantial increase in serum
leptin concentrations in minimal and moderate-advanced
cases. However, in all the three groups of patients, there were
no statistically signiﬁcant diﬀerences in serum TNF-α and
leptin levels before and after the therapy.
The patients with sequelae lesions had lower leptin con-
centrations after anti-TB therapy (2.13 ± 1.96) than the pa-
tients with no squelae lesions (6.9 ± 5.72ng/dL, P<. 05)
but the concentrations of TNF-α and BMI between the
groups were similar (Table 4). There were no statistically
signiﬁcant diﬀerences in these parameters between the pa-
tients with cavity and without cavity. In the patients, there
was no correlation for TNF-α and leptin levels with body
mass index, age, fever, and ESR. There was no statisti-
cally signiﬁcant diﬀerence between the extent of lesions and
age.
4. DISCUSSION
Tuberculosis symptoms may be divided into two categories,
systemic and pulmonary. Cough, anorexia, and weight loss
are the most common symptoms of TB. The systemic symp-
tommostfrequentlyobservedisalow-gradefever.Othersys-
temic symptoms such as sweating (night sweat), weakness,
fatigue, and headache may be present [13].
The anorexia during infection is part of the general-
ized host defense reaction. Despite being beneﬁcial in the
beginning, persistent anorexia delays recovery and is ulti-
mately deleterious. Microbial products such as bacterial cell
wall compounds (e.g., lipopolysaccharides), microbial nu-
cleic acids (e.g., DNA, RNA), and viral glycoproteins cause
the anorexia during infections. Microbial products stimulate
the production of proinﬂamatory cytokines (e.g., ILs, TNF-
α). Several cytokines reduce food intake after parenteral ad-
ministration, suggesting that their enhanced production in
respons to microbial products contributes to the anorexia of
infection [14].
TNF-α induces fever and weight loss, which are typical
symptoms of TB [15]. It has been shown to be associated
with both protection and pathogenesis in mycobacterial in-
fections [15, 16]. Several studies have shown that the sys-
temic administration of recombinant TNF increases leptin
gene expression from fat tissue [17, 18]. We found higher
levels of TNF-α and low levels of leptin in TB patient group
comparedtocontrolindicating nosigniﬁcantassociationbe-
tween these two parameters.
Recent ﬁndings support the hypothesis that cytokine in-
duction of leptin may play a signiﬁcant role in anorexia
and cachexia of inﬂammatory diseases and cancer. Micro-
bial products and cytokines such as TNF and IL-1 increase
leptin expression dose dependently in adipose tissue [18].
The cytokine-induced increase in leptin expression or its
serum levels and reduction in food intake are closely related.
Acuteinﬂammatorystimulisuchassurgicalcholecystectomy
have been shown to increase leptin levels in humans [19].4 Mediators of Inﬂammation
Table 3: TNF-α and leptin levels according to chest X-ray scores. Data presented as mean ± SD.
TNF-α Leptin
Before therapy After therapy P Before therapy After therapy P
Minimal (n = 8) 22.07 ±8.04 16.18 ±7.64 NS 2.39 ±2.57 5.67 ±5.60 <. 05
Moderate-advanced (n = 10) 22.44 ±12.19 17.46 ±6.01 NS 1.37 ±1.06 3.32 ±2.0 <. 05
Far-advanced (n = 7) 25.54 ±18.61 13.54 ±6.36 NS 1.24 ±0.89 1.15 ±0.88 NS
P∗ NS NS — NS NS —
∗Comparison between three groups of TNF and leptin levels.
NS = not signiﬁcant P>. 05.
Table 4: Serum leptin and TNF-α levels in patients with sequelae lesions and cavitary tuberculosis. Data presented as mean ±SD.
Sequelae lesion No sequelae lesion Cavity No cavity
n = 6 n = 19 n = 7 n = 18
Age 36.22 ±16.43 35.42 ± 9.76 35.71 ±18.40 36.11 ±13.56
BMI 19.0 ±2.74 20.3 ±1.86 18.20 ±3.71 19.82 ±1.89
BMI∗ 22.42 ±3.21 24.01 ± 2.79 22.0 ±4.89 23.21 ±2.22
Leptin 1.29 ±0.85 2.61 ±2.79 1.52 ±1.13 1.71 ±1.87
Leptin∗ 2.13 ±1.96 6.9 ±5.72¶ 3.06 ±3.54 3.62 ±4.19
TNF-α 22.1 ±13.07 25.98 ±12.54 21.36 ±11.15 23.9 ±13.60
TNF-α∗ 16.49 ±6.65 14.57 ± 6.70 14.44 ±6.56 16.54 ±6.69
¶P<. 05.
∗Levels of parameters after antituberculosis therapy.
However, in chronic inﬂammatory and infectious diseases
such as AIDS, rheumatoid arthritis, and inﬂammatory bowel
disease, no changes in leptin levels have been observed [20–
22]. C ¸akir et al. [23] have found increased levels of TNF-α
and leptin in tuberculosis patients with good correlation of
these two parameters and interpreted that the eleveted lep-
tin level leads to weight loss, and may therefore contribute
to the inﬂammatory process. Conversely, we found reduced
leptin levels in TB patients both before and after the treat-
ment. Although previous data have shown that plasma lep-
tin levels are associated with loss of appetite in pulmonary
tuberculosis, we were unable to demonstrate signiﬁcant cor-
relation between plasma leptin levels and loss of appetite
[24].
Initially, leptin was considered as an antiobesity hor-
mone, but experimental evidence has also shown pleiotropic
eﬀects of this molecule on hematopoiesis, angiogenesis, and
T lymphocyte functions [5, 7, 9]. Leptin belongs structurally
to the long-chain helical cytokine family such as inter-IL-2,
IL-12, and the growth hormone [8]. Leptin links the proin-
ﬂammatory Th1 immune response to the nutritional sta-
tus and the energy balance [8, 11]. Ob/ob mice display im-
mune defects with lymphoid organ atrophy, mainly aﬀecting
thymic size and cellularity [25]. Leptin deﬁciency is respon-
sible for immunosuppression and reduced T cell response
to microorganisms [9, 24] Leptin replacement reverses the
immunosuppressive eﬀect of acute food deprivation in mice
[25].
In a recent study, morbidly obese children, who were
congenitally deﬁcient in leptin, have reduced number of cir-
culating CD4 T cell and impaired T cell proliferation and
cytokine release, which were reversed by daily subcutaneous
injections of recombinant human leptin [26]. Leptin lev-
els were found to be elevated in patients with sepsis and
low leptin levels in patients with sepsis and septic shock
are signiﬁcantly associated with high mortality [27]. As cell-
mediated immunity (CD4 T-helper-response and interferon
(INF)-gamma) play an essential role in M. tuberculosis in-
fection [28, 29], any impairment in T cell proliferation due
to reduced leptin concentrations may contribute to the de-
velopment of tuberculosis. In our patient group, both be-
fore and after treatment, leptin levels were suppressed, sup-
porting the concept that leptin induction represents a pro-
tective component of the immune response in pulmonary
tuberculosis. Conﬂicting data have been reported for leptin
levels during infection. Eleveted leptin levels were detected
in the studies published by C ¸akir et al. [23]a n dY ¨ uksel et
al.[30].Ontheotherhand,VanCreveletal.[24]haveshown
that both plasma leptin and ex vivo IFN-gamma produc-
tion were low and increased upon successful antituberculous
treatment. Schwenk et al. [31] did not ﬁnd any correlation
between serum IL-6, TNF-α, and leptin levels.
Inthepresentstudy,wecouldnotﬁndanycorrelationbe-
tweenTNF-α,leptinconcentration,andchestX-rayﬁndings.
Tsao et al. [32] studied bronchoalveolar lavage (BAL) ﬂuid
and serum TNF-α,I L 1 β,a n dT N F - α receptor levels in pa-
tients with cavitated and noncavitated tuberculosis. The BAL
ﬂuid TNF-α,I L 1 β,a n dT N F - α receptor levels were higher in
patienst with cavitated tuberculosis, but there was no such
diﬀerence in serum levels. We also could not ﬁnd any dif-
ference in the serum leptin concentration and TNF-α lev-
els of cavitated and noncavitated tuberculosois patients. OnH a k a nB u y u k o g l a ne ta l . 5
the control chest X-rays obtained after anti-TB therapy, se-
quele lesions lie chronic ﬁbrotic changes were detected in 19
patients. There was no diﬀerence in the ESR, BMI, and TNF-
α levels of patients with and without sequele, but the leptin
concentration was signiﬁcantly low in patients with sequele.
Wepresumethatthesequelaelesionsaretheresultofreduced
inﬂammatory response due to low leptin concentration. But
we do not know the duration of low leptin concentration in
patientswithsequelae.Wealsodonotknowwhetherlowlep-
tin concentration has any contribution in patients with re-
lapse. We believe that further studies are needed to answer
these questions.
In conclusion, leptin release is suppressed in tuberculo-
sis and probably low leptin concentrations may contribute to
the increased infection susceptibility and recovery with se-
quele lesions in patients with tuberculosis.
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